In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.
Did you know that your browser is out of date? To get the best experience using our website we recommend that you upgrade to a newer version. Learn more.

We use cookies to optimise the design of this website and make continuous improvement. By continuing your visit, you consent to the use of cookies. Learn more

Preventing sudden death in hypertrophic cardiomyopathy: new backing for ESC guidelines (HCM-EVIDENCE)



Barcelona, Spain – 29 Aug 2017: A large study conducted across North America, Europe, the Middle East and Asia has validated the ESC recommendations for predicting and preventing sudden cardiac death (SCD) in patients with hypertrophic cardiomyopathy (HCM).

The HCM-EVIDENCE study, presented at ESC Congress 2017 (1), tested the ESC’s recommendations in a diverse cohort of patients, said study investigator Constantinos O’Mahony, MRCP(UK).

“Since 2014, the ESC has recommended using a special risk prediction tool called the HCM Risk-SCD to identify which patients are at highest risk for sudden death and would benefit most from having a prophylactic implantable cardioverter defibrillator,” explained Dr O’Mahony, from St. Bartholomew’s Centre for Inherited Cardiovascular Disease, St Bartholomew’s Hospital, and the University College London Centre for Heart Muscle Disease, Institute of Cardiovascular Science, London.

“But, whenever a risk model is created, there are concerns about how generalisable it is outside the original study population. Since we developed the HCM Risk-SCD tool using patients treated exclusively in Europe, it was important for us to demonstrate its applicability in other healthcare systems with different medical expertise and potentially different patterns of disease.”
 
ESC guidelines recommend using the HCM Risk–SCD risk calculator to estimate a patient’s 5-year risk of SCD, with the recommendation that high-risk patients receive implantable cardioverter defibrillators (ICD) to prevent fatal ventricular arrhythmias.

For the current study, investigators retrospectively evaluated 3,703 patients to see if their HCM Risk–SCD score accurately predicted whether they eventually went on to suffer SCD.

Overall, the analysis showed that the tool could distinguish well between high- and low- risk patients, with  good agreement between what it predicted and their actual 5-year SCD rates.

Specifically, patients classified as low risk (predicted to have a SCD incidence of <4% at 5 years) , had a  5-year SCD incidence of 1.4%, while those classified as high risk (predicted to have a SCD incidence ≥6% at 5 years) had an incidence of 8.9%.

“We calculated that for every 13 high-risk patients who receive an ICD as recommended by ESC guidelines, one patient could potentially be saved from SCD,” noted Dr. O’Mahony.

“The study also shows that the HCM Risk-SCD calculator can be used to avoid unnecessary ICD implants in low risk patients, supporting the 2014 ESC recommendation not to implant ICDs in these individuals.”

He emphasised that despite the good prognostic performance of the HCM Risk–SCD calculator, no strategy will ever be able to predict and prevent all SCDs, especially for intermediate risk patients (defined as a 5-year SCD risk of 4-6%).
 
Nevertheless, “quantification of risk enhances the shared decision-making process,” he concluded.

ENDS

Notes to editor

Sources of funding: University College London received a proportion of funding from the United Kingdom Department of Health's National Institute for Health Research Biomedical Research Centres funding scheme and St Bartholomew’s Hospital, London.

Disclosures: Dr. O’Mahony has no relevant disclosures.

References and notes
(1) The study “An international external validation study of the 2014 european society of cardiology guideline on sudden cardiac death prevention in hypertrophic cardiomyopathy” will be presented during:
·    The Press Conference Hot Line - Late Breaking Registry Results 1 on Tuesday 29 August from 8:00 to 9:00
·    The session Hot Line: Late-Breaking Registry Results 1 on Tuesday 29 August from 11:00 to 12:30 in Barcelona, Main Auditorium.

ESC Press Office
For more information, please contact the ESC Press Office: press@escardio.org.
For press enquiries, independent comment on-site, please contact, the Media & Press Coordinator Jacques Olivier COSTA: +34 666 509 856
The press conference timetable is available here.

To access all the scientific resources from the sessions during the congress, visit ESC Congress 365.  

About the European Society of Cardiology
The European Society of Cardiology brings together health care professionals from more than 140 countries, working to advance cardiovascular medicine and help people lead longer, healthier lives.

About ESC Congress 2017
ESC Congress is the world’s largest and most influential cardiovascular event contributing to global awareness of the latest clinical trials and breakthrough discoveries. ESC Congress 2017 takes place 26 to 30 August at the Fira Gran Via in Barcelona, Spain. The scientific programme is here. More information is available from the ESC Press Office at press@escardio.org.

This press release accompanies both a presentation and an ESC press conference at the ESC Congress 2017. Edited by the ESC from material supplied by the investigators themselves, this press release does not necessarily reflect the opinion of the European Society of Cardiology. The content of the press release has been approved by the presenter.